Comprehensive T cell repertoire characterization of non-small cell lung cancer.

Adult Aged Carcinoma, Non-Small-Cell Lung / immunology Clone Cells ErbB Receptors / genetics Female Humans Lung / pathology Lung Neoplasms / immunology Lymphocyte Activation / immunology Lymphocyte Count Male Middle Aged Mutation / genetics Survival Analysis T-Lymphocytes / immunology

Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
30 01 2020
Historique:
received: 01 05 2019
accepted: 17 12 2019
entrez: 1 2 2020
pubmed: 1 2 2020
medline: 14 4 2020
Statut: epublish

Résumé

Immunotherapy targeting T cells is increasingly utilized to treat solid tumors including non-small cell lung cancer (NSCLC). This requires a better understanding of the T cells in the lungs of patients with NSCLC. Here, we report T cell repertoire analysis in a cohort of 236 early-stage NSCLC patients. T cell repertoire attributes are associated with clinicopathologic features, mutational and immune landscape. A considerable proportion of the most prevalent T cells in tumors are also prevalent in the uninvolved tumor-adjacent lungs and appear specific to shared background mutations or viral infections. Patients with higher T cell repertoire homology between the tumor and uninvolved tumor-adjacent lung, suggesting a less tumor-focused T cell response, exhibit inferior survival. These findings indicate that a concise understanding of antigens and T cells in NSCLC is needed to improve therapeutic efficacy and reduce toxicity with immunotherapy, particularly adoptive T cell therapy.

Identifiants

DOI: 10.1038/s41467-019-14273-0 PMID: 32001676 PMC: PMC6992630
pubmed: 32001676
doi: 10.1038/s41467-019-14273-0
pii: 10.1038/s41467-019-14273-0
pmc: PMC6992630
doi:

Substances chimiques

ErbB Receptors EC 2.7.10.1

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

603

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA070907
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA234629
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States

Références

Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).
pubmed: 23945592 pmcid: 23945592 doi: 10.1038/nature12477
Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214–218 (2013).
pubmed: 23770567 pmcid: 3919509 doi: 10.1038/nature12213
Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189–2199 (2014).
pubmed: 25409260 pmcid: 4315319 doi: 10.1056/NEJMoa1406498
Tran, E. et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science (New York, NY) 344, 641–645 (2014).
doi: 10.1126/science.1251102
Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
pubmed: 20525992 pmcid: 3549297 doi: 10.1056/NEJMoa1003466
Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012).
pubmed: 22658127 pmcid: 3544539 doi: 10.1056/NEJMoa1200690
Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455–2465 (2012).
pubmed: 22658128 pmcid: 3563263 doi: 10.1056/NEJMoa1200694
Wang, R. F. & Rosenberg, S. A. Human tumor antigens for cancer vaccine development. Immunol. Rev. 170, 85–100 (1999).
pubmed: 10566144 doi: 10.1111/j.1600-065X.1999.tb01331.x pmcid: 10566144
Rosenberg, S. A. & Restifo, N. P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science (New York, NY) 348, 62–68 (2015).
doi: 10.1126/science.aaa4967
Robins, H. S. et al. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood 114, 4099–4107 (2009).
pubmed: 19706884 pmcid: 2774550 doi: 10.1182/blood-2009-04-217604
Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014).
pubmed: 25428505 pmcid: 25428505 doi: 10.1038/nature13954
Roh, W. et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci. Transl. Med. 9, 1–11 (2017).
doi: 10.1126/scitranslmed.aah3560
Chiu, C. & Openshaw, P. J. Antiviral B cell and T cell immunity in the lungs. Nat. Immunol. 16, 18–26 (2015).
pubmed: 25521681 doi: 10.1038/ni.3056 pmcid: 25521681
Lavin, Y. et al. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell 169, 750–765 e717 (2017).
pubmed: 28475900 pmcid: 5737939 doi: 10.1016/j.cell.2017.04.014
Kargl, J. et al. Neutrophils dominate the immune cell composition in non-small cell lung cancer. Nat. Commun. 8, 14381 (2017).
pubmed: 28146145 pmcid: 5296654 doi: 10.1038/ncomms14381
Choi, M. et al. Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol. / ESMO 28, 83–89 (2017).
doi: 10.1093/annonc/mdw437
Kadara, H. et al. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Ann. Oncol. 28, 75–82 (2017).
pubmed: 31792518 doi: 10.1093/annonc/mdw436 pmcid: 31792518
Parra, E. R. et al. Image analysis-based assessment of PD-L1 and tumor-associated immune cells density supports distinct intratumoral microenvironment groups in non-small cell lung carcinoma patients. Clin. Cancer Res. 22, 6278–6289 (2016).
pubmed: 27252415 pmcid: 5558040 doi: 10.1158/1078-0432.CCR-15-2443
Tang, H. et al. A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients. Clin. Cancer Res. 19, 1577–1586 (2013).
pubmed: 23357979 pmcid: 3619002 doi: 10.1158/1078-0432.CCR-12-2321
Lou, Y. et al. Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clin. Cancer Res. 22, 3630–3642 (2016).
pubmed: 26851185 pmcid: 4947453 doi: 10.1158/1078-0432.CCR-15-1434
Reuben, A. et al. TCR repertoire intratumor heterogeneity in localized lung adenocarcinomas: an association with predicted neoantigen heterogeneity and postsurgical recurrence. Cancer Discov. 7, 1088–1097 (2017).
pubmed: 28733428 pmcid: 5628137 doi: 10.1158/2159-8290.CD-17-0256
Qi, Q. et al. Diversity and clonal selection in the human T-cell repertoire. Proc. Natl Acad. Sci. USA 111, 13139–13144 (2014).
pubmed: 25157137 doi: 10.1073/pnas.1409155111 pmcid: 25157137
Feldmeyer, L. et al. Density, distribution, and composition of immune infiltrates correlate with survival in merkel cell carcinoma. Clin. Cancer Res. 22, 5553–5563 (2016).
pubmed: 27166398 pmcid: 5857157 doi: 10.1158/1078-0432.CCR-16-0392
Zhang, J. et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science (New York, NY) 346, 256–259 (2014).
doi: 10.1126/science.1256930
McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science (New York, NY) 351, 1463–1469 (2016).
pmcid: 4984254 doi: 10.1126/science.aaf1490
Hellmann, M. D. et al. Nivolumab plus Ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med. 378, 2093–2104 (2018).
pubmed: 29658845 doi: 10.1056/NEJMoa1801946 pmcid: 29658845
Carbone, D. P. et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N. Engl. J. Med. 376, 2415–2426 (2017).
pubmed: 28636851 pmcid: 6487310 doi: 10.1056/NEJMoa1613493
Stratton, M. R., Campbell, P. J. & Futreal, P. A. The cancer genome. Nature 458, 719–724 (2009).
pubmed: 19360079 pmcid: 2821689 doi: 10.1038/nature07943
Skoulidis, F. et al. STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Disco. 8, 822–835 (2018).
doi: 10.1158/2159-8290.CD-18-0099
Liu, C. et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin. Cancer Res. 19, 393–403 (2013).
pubmed: 23204132 doi: 10.1158/1078-0432.CCR-12-1626 pmcid: 23204132
Lee, C. K. et al. Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis. JAMA Oncol. 4, 210–216 (2018).
pubmed: 29270615 doi: 10.1001/jamaoncol.2017.4427 pmcid: 29270615
Lee, C. K. et al. Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer—a meta-analysis. J. Thorac. Oncol.: Off. Publ. Int. Assoc. Study Lung Cancer 12, 403–407 (2017).
doi: 10.1016/j.jtho.2016.10.007
Gainor, J. F. et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin. Cancer Res. 22, 4585–4593 (2016).
pubmed: 27225694 pmcid: 5026567 doi: 10.1158/1078-0432.CCR-15-3101
D'Incecco, A. et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br. J. Cancer 112, 95–102 (2015).
pubmed: 25349974 doi: 10.1038/bjc.2014.555 pmcid: 25349974
Azuma, K. et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann. Oncol. 25, 1935–1940 (2014).
pubmed: 25009014 doi: 10.1093/annonc/mdu242 pmcid: 25009014
Simoni, Y. et al. Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature 557, 575–579 (2018).
pubmed: 29769722 doi: 10.1038/s41586-018-0130-2 pmcid: 29769722
Glanville, J. et al. Identifying specificity groups in the T cell receptor repertoire. Nature 547, 94–98 (2017).
pubmed: 28636589 pmcid: 5794212 doi: 10.1038/nature22976
Park, J. H. et al. Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy. Int. J. Oncol. 49, 471–478 (2016).
pubmed: 27278091 pmcid: 4922832 doi: 10.3892/ijo.2016.3540
Ikeda, Y. et al. Clinical significance of T cell clonality and expression levels of immune-related genes in endometrial cancer. Oncol. Rep. 37, 2603–2610 (2017).
pubmed: 28358435 pmcid: 5428285 doi: 10.3892/or.2017.5536
Rosenberg, S. A. et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17, 4550–4557 (2011).
pubmed: 21498393 pmcid: 3131487 doi: 10.1158/1078-0432.CCR-11-0116
Carlson, C. S. et al. Using synthetic templates to design an unbiased multiplex PCR assay. Nat. Commun. 4, 2680 (2013).
pubmed: 24157944 doi: 10.1038/ncomms3680 pmcid: 24157944
Robins, H. et al. Ultra-sensitive detection of rare T cell clones. J. Immunol. Methods 375, 14–19 (2012).
pubmed: 21945395 doi: 10.1016/j.jim.2011.09.001 pmcid: 21945395
Kirsch, I., Vignali, M. & Robins, H. T-cell receptor profiling in cancer. Mol. Oncol. 9, 2063–2070 (2015).
pubmed: 26404496 pmcid: 5528728 doi: 10.1016/j.molonc.2015.09.003
DeWitt, W. S. et al. Dynamics of the cytotoxic T cell response to a model of acute viral infection. J. Virol. 89, 4517–4526 (2015).
pubmed: 25653453 pmcid: 4442358 doi: 10.1128/JVI.03474-14
Shugay, M. et al. VDJdb: a curated database of T-cell receptor sequences with known antigen specificity. Nucleic Acids Res. 46, D419–D427 (2018).
pubmed: 28977646 doi: 10.1093/nar/gkx760 pmcid: 28977646
Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213–219 (2013).
pubmed: 23396013 pmcid: 3833702 doi: 10.1038/nbt.2514
Ye, K., Schulz, M. H., Long, Q., Apweiler, R. & Ning, Z. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics 25, 2865–2871 (2009).
pubmed: 2781750 pmcid: 2781750 doi: 10.1093/bioinformatics/btp394
Takahashi, K. et al. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol. 18, 100–111 (2017).
pubmed: 27923552 doi: 10.1016/S1470-2045(16)30626-X pmcid: 27923552
Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488–2498 (2014).
pubmed: 25426837 pmcid: 4306669 doi: 10.1056/NEJMoa1408617
Bai, Y., Wang, D. & Fury, W. PHLAT: inference of high-resolution HLA types from RNA and whole exome sequencing. Methods Mol. Biol. 1802, 193–201 (2018).
pubmed: 29858810 doi: 10.1007/978-1-4939-8546-3_13 pmcid: 29858810
McGranahan, N. et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell 171, 1259–1271 e1211 (2017).
pubmed: 29107330 pmcid: 5720478 doi: 10.1016/j.cell.2017.10.001
Favero, F. et al. Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data. Ann. Oncol. : Off. J. Eur. Soc. Med. Oncol. / ESMO 26, 64–70 (2015).
doi: 10.1093/annonc/mdu479
Xie, Y., Wang, X. & Story, M. Statistical methods of background correction for Illumina BeadArray data. Bioinformatics 25, 751–757 (2009).
pubmed: 19193732 pmcid: 2654805 doi: 10.1093/bioinformatics/btp040

Auteurs

Alexandre Reuben (A)

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
ORCID: 0000-0003-4510-0382

Jiexin Zhang (J)

Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
ORCID: 0000-0001-9526-6730

Shin-Heng Chiou (SH)

Institute for Immunity, Transplantation, and Infection Operations, Howard Hughes Medical Institute, 450 Serra Mall, Stanford, CA, 94305, USA.

Rachel M Gittelman (RM)

Adaptive Biotechnologies, 1551 Eastlake Ave East, Seattle, WA, 98102, USA.

Jun Li (J)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.

Won-Chul Lee (WC)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
ORCID: 0000-0003-3913-8632

Junya Fujimoto (J)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.

Carmen Behrens (C)

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.

Xiaoke Liu (X)

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.

Feng Wang (F)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.

Kelly Quek (K)

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
ORCID: 0000-0002-8113-0944

Chunlin Wang (C)

iRepertoire, Inc., 800 Hudson Way, Suite 2304, Huntsville, AL, 35806, USA.

Farrah Kheradmand (F)

Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA.

Runzhe Chen (R)

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.

Chi-Wan Chow (CW)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.

Heather Lin (H)

Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.

Chantale Bernatchez (C)

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.

Ali Jalali (A)

Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.

Xin Hu (X)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.

Chang-Jiun Wu (CJ)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.

Agda Karina Eterovic (AK)

Department of Systems Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.

Edwin Roger Parra (ER)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
ORCID: 0000-0001-9068-1636

Erik Yusko (E)

Adaptive Biotechnologies, 1551 Eastlake Ave East, Seattle, WA, 98102, USA.

Ryan Emerson (R)

Adaptive Biotechnologies, 1551 Eastlake Ave East, Seattle, WA, 98102, USA.

Sharon Benzeno (S)

Adaptive Biotechnologies, 1551 Eastlake Ave East, Seattle, WA, 98102, USA.

Marissa Vignali (M)

Adaptive Biotechnologies, 1551 Eastlake Ave East, Seattle, WA, 98102, USA.

Xifeng Wu (X)

Department of Epidemiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.

Yuanqing Ye (Y)

Department of Epidemiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.

Latasha D Little (LD)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.

Curtis Gumbs (C)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.

Xizeng Mao (X)

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.

Xingzhi Song (X)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.

Samantha Tippen (S)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.

Rebecca L Thornton (RL)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.

Tina Cascone (T)

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.

Alexandra Snyder (A)

Adaptive Biotechnologies, 1551 Eastlake Ave East, Seattle, WA, 98102, USA.

Jennifer A Wargo (JA)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
ORCID: 0000-0003-3438-7576

Roy Herbst (R)

Department of Medical Oncology, 333 Cedar Street, Yale Cancer Center, New Haven, CT, 06510, USA.

Stephen Swisher (S)

Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
ORCID: 0000-0002-3080-1920

Humam Kadara (H)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.

Cesar Moran (C)

Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.

Neda Kalhor (N)

Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.

Jianhua Zhang (J)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.

Paul Scheet (P)

Department of Epidemiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.

Ara A Vaporciyan (AA)

Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.

Boris Sepesi (B)

Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.

Don L Gibbons (DL)

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.

Harlan Robins (H)

Adaptive Biotechnologies, 1551 Eastlake Ave East, Seattle, WA, 98102, USA.
Computational Biology Program, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave North, Seattle, WA, 98109, USA.

Patrick Hwu (P)

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.

John V Heymach (JV)

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.

Padmanee Sharma (P)

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
Department of Immunology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.

James P Allison (JP)

Department of Immunology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.

Veera Baladandayuthapani (V)

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.

Jack J Lee (JJ)

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA.
ORCID: 0000-0001-5469-9214

Mark M Davis (MM)

Department of Microbiology and Immunology, Howard Hughes Medical Institute, Stanford, 450 Serra Mall, Stanford, CA, 94305, USA. mmdavis@stanford.edu.
ORCID: 0000-0001-6868-657X

Ignacio I Wistuba (II)

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA. iiwistuba@mdanderson.org.
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA. iiwistuba@mdanderson.org.

P Andrew Futreal (PA)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA. afutreal@mdanderson.org.
ORCID: 0000-0001-8663-2671

Jianjun Zhang (J)

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA. jzhang20@mdanderson.org.
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX, 77030, USA. jzhang20@mdanderson.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Comprehensive T cell repertoire...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Comprehensive T cell repertoire...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Tumeurs des bronches › Carcinome bronchogénique › Carcinome pulmonaire non à petites cellules › Comprehensive T cell repertoire...
questionsmedicales.fr › Cellules › Cellules cultivées › Clones cellulaires › Comprehensive T cell repertoire...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteur facteur croissance › Récepteurs ErbB › Comprehensive T cell repertoire...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Comprehensive T cell repertoire...
questionsmedicales.fr › Appareil respiratoire › Poumon › Comprehensive T cell repertoire...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Comprehensive T cell repertoire...
questionsmedicales.fr › Phénomènes du système immunitaire › Activation des lymphocytes › Comprehensive T cell repertoire...
questionsmedicales.fr › Phénomènes physiologiques respiratoires et circulatoires › Phénomènes physiogiques du sang › Hémogramme › Numération des leucocytes › Numération des lymphocytes › Comprehensive T cell repertoire...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Comprehensive T cell repertoire...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Comprehensive T cell repertoire...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Comprehensive T cell repertoire...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Comprehensive T cell repertoire...